Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05134636 · ClinicalTrials.gov registry record · NA

Text-based Intervention to Minimize the Time Burden of Routine Cancer Care

A NA study, sponsored by Abramson Cancer Center at Penn Medicine.

Completed
Registry status
NA
Development phase
40
Enrollment target

NCT05134636 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05134636, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

The primary objective is to test whether a text-based e-triage can safely minimize the time associated with routine cancer care by identifying patients who can proceed directly to their immunotherapy infusion without a preceding in-person office assessment.

Interventions

  • OTHER Text triage

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2021-12-06
Est. Completion 2022-12-12
Phase NA

What the Registry Record Tells You About NCT05134636

The ClinicalTrials.gov registry entry for NCT05134636 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Text triage is the first listed.

NCT05134636 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05134636 about?

NCT05134636 is a clinical study titled "Text-based Intervention to Minimize the Time Burden of Routine Cancer Care". The primary objective is to test whether a text-based e-triage can safely minimize the time associated with routine cancer care by identifying patients who can proceed directly to their immunotherapy infusion without a preceding in-person office assessment.

What is the current status of trial NCT05134636?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-12-06. Estimated completion is 2022-12-12.

What interventions are being tested in trial NCT05134636?

The interventions under investigation include: Text triage (OTHER).

Who is sponsoring clinical trial NCT05134636?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.